A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to compare the safety and effectiveness of Prograf in the prevention of erectile dysfunction in men after a radical prostatectomy.
| Condition | Intervention | Phase |
|---|---|---|
|
Erectile Dysfunction Prostate Cancer |
Drug: Tacrolimus Drug: Placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy |
- Erectile Function Domain Score Between Treated and Untreated Groups [ Time Frame: 18 months ] [ Designated as safety issue: No ]Erectile function was assessed using the International Index of Erectile Function (IIEF) questionnaire, which consists of 15 questions. The erectile function domain score is calculated as a sum of scores from questions 1-5 and 15. A clinically meaningful difference is 5 points. The scores range from 1 to 30 points where a higher score indicates better erectile function. Normal erectile function is defined as greater than or equal to 24 points.
- Percentage of Patients Achieving Normal Spontaneous Erectile Function as Measured by the Erectile Function (EF) Domain Score [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Erectile function was assessed using the International Index of Erectile Function (IIEF) questionnaire, which consists of 15 questions. The erectile function domain score is calculated as a sum of scores from questions 1-5 and 15. A clinically meaningful difference is 5 points. The scores range from 1 to 30 points where a higher score indicates better erectile function. Normal erectile function is defined as greater than or equal to 24 points.
Percentages represent the proportions of participants who achieved normal erectile function at any time during the 24 months.
- Time Taken to Achieve Normalization of the Erectile Function (EF) Domain Score [ Time Frame: 24 months ] [ Designated as safety issue: No ]Erectile function was assessed using the International Index of Erectile Function (IIEF) questionnaire, which consists of 15 questions. The EF domain score is calculated as a sum of scores from questions 1-5 and 15. A clinically meaningful difference is 5 points. Scores range from 1-30 points where a higher score indicates better erectile function. Normal erectile function is defined as greater than or equal to 24 points.Time to achieve normalization of the EF domain score was calculated based on the date of the assessment during which the EF domain score was first greater than or equal to 24.
- Percentage of Patients Considered Successful Responders to Impotence Medications [ Time Frame: 24 months ] [ Designated as safety issue: No ]Patients were identified as successful responders if they answered affirmatively in the Patient Sexual Encounter Diary regarding successful sexual intercourse after using impotence medication.
- Time to Achieve Response to Impotence Medications [ Time Frame: 24 months ] [ Designated as safety issue: No ]Time to achieve response to impotence medication was calculated based on the date of the assessment during which the first successful response was recorded. The specific date of the actual response is not reflected; only that it occurred since the previous study visit.
- Continence Level as Quantified by Part I of the Prostate Health-Related Quality of Life Questionnaire [ Time Frame: 24 months ] [ Designated as safety issue: No ]Part 1 Urinary Function- Prostate Health-Related Quality-of-Life (QOL) Questionnaire consists of 16 questions asking patients about their continence and urinary habits over the previous four weeks. The responses to all 16 of these questions were added together to calculate an overall score for urinary function. The minimum possible score is 16 and the maximum possible score is 79. A higher score indicates a lower continence level.
| Enrollment: | 131 |
| Study Start Date: | February 2005 |
| Study Completion Date: | November 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tacrolimus
Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
|
Drug: Tacrolimus
oral
Other Name: Prograf, FK506
|
|
Placebo Comparator: Placebo
Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.
|
Drug: Placebo
oral
|
Detailed Description:
The purpose of the study is to compare the safety and efficacy of Prograf versus placebo in the prevention of erectile dysfunction in men after a bilateral nerve-sparing radical prostatectomy.
Eligibility| Ages Eligible for Study: | up to 65 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male scheduled to undergo bilateral nerve sparing radical prostatectomy for prostate cancer.
Exclusion Criteria:
- Patient is > 65 years of age
- Patient has been diagnosed with Type 1 or Type 2 diabetes
- Patient is actively smoking on a daily basis
Contacts and Locations| United States, Michigan | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, New York | |
| New York, New York, United States, 10021 | |
| New York, New York, United States, 10016 | |
| United States, Ohio | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Tennessee | |
| Nashville, Tennessee, United States, 37232 | |
| United States, Texas | |
| Houston, Texas, United States, 77030 | |
| Study Director: | Central Contact | Astellas Pharma US, Inc. |
More Information
Additional Information:
No publications provided
| Responsible Party: | Sr Manager Clinical Trial Registries, Astellas Pharma US, Inc |
| ClinicalTrials.gov Identifier: | NCT00106392 History of Changes |
| Other Study ID Numbers: | 20-03-001 |
| Study First Received: | March 23, 2005 |
| Results First Received: | September 30, 2010 |
| Last Updated: | November 15, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Astellas Pharma Inc:
|
Treatment effectiveness Treatment efficacy Investigational, Therapies |
Immunosuppressant Erectile dysfunction Prostatectomy |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Erectile Dysfunction Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Sexual Dysfunction, Physiological |
Sexual Dysfunctions, Psychological Sexual and Gender Disorders Mental Disorders Tacrolimus Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013